Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 52.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 418 shares of the life sciences company’s stock after selling 465 shares during the quarter. Blue Trust Inc.’s holdings in Illumina were worth $56,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Chevy Chase Trust Holdings LLC increased its position in Illumina by 8.3% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 526,414 shares of the life sciences company’s stock worth $70,345,000 after purchasing an additional 40,219 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after buying an additional 132 shares during the last quarter. Vontobel Holding Ltd. raised its position in Illumina by 12.5% during the fourth quarter. Vontobel Holding Ltd. now owns 5,941 shares of the life sciences company’s stock valued at $794,000 after acquiring an additional 660 shares in the last quarter. Asset Management One Co. Ltd. raised its position in Illumina by 9.4% during the fourth quarter. Asset Management One Co. Ltd. now owns 97,042 shares of the life sciences company’s stock valued at $13,127,000 after acquiring an additional 8,299 shares in the last quarter. Finally, Tranquility Partners LLC lifted its stake in Illumina by 107.6% in the fourth quarter. Tranquility Partners LLC now owns 3,656 shares of the life sciences company’s stock valued at $489,000 after acquiring an additional 1,895 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ILMN. Robert W. Baird raised their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Piper Sandler increased their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. JPMorgan Chase & Co. lifted their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $130.00 to $100.00 in a report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Stock Up 1.9 %

ILMN stock opened at $95.73 on Wednesday. The company has a market cap of $15.16 billion, a price-to-earnings ratio of -12.46, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business’s 50-day moving average is $126.02 and its two-hundred day moving average is $133.80. Illumina, Inc. has a fifty-two week low of $91.92 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.